Compare Eli Lilly And Co (LLY) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prudential Financial Inc — how do they compare? Eli Lilly And Co trades at $1,159.69 (market cap $1.02T), while Prudential Financial Inc trades at $118.36 (market cap $40.97B). The key difference: Eli Lilly And Co is far larger — about 24.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| LLY | PRU | |
|---|---|---|
Market Cap | $1.02T | $40.97B |
Sector | Health | Financials |
52-Week High | $1.24K | $119.07 |
52-Week Low | $625.65 | $92.00 |
Enterprise Value | $1.06T | $68.03B |
Dividend Yield | 0.6% | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Prudential Financial (PRU) trades at $118.04, down 0.87% on the day, showing mixed technical signals with a bullish overall trend but overbought RSI indicators. Fundamentally, the company demonstrates solid profitability with 5.5% net income margin and 11.08% ROE, though revenue declined from $70.7B in 2024 to $61.0B in 2025. Recent earnings show beats in Q3 2025 and Q1 2026, with Q2 2026 results expected August 4, 2026.
The stock presents a value opportunity with attractive valuation multiples (P/E 12.26, P/S 0.67) but faces headwinds from analyst skepticism (67.57% hold rating) and a consensus price target of $102.50 below current levels. Key risks include revenue volatility and high debt levels, while catalysts include retirement market growth and international expansion driving long-term earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
